The genetics of a pharma merger

The 1990s and early years of this century have seen a series of large-scale mergers and acquisitions in the Pharmaceutical and Biotech arena. These activities each required integration at multiple levels. One of the most important activities is the integration of the R&D pipelines of the partici...

Full description

Saved in:
Bibliographic Details
Published inDrug discovery today Vol. 14; no. 7; pp. 334 - 336
Main Authors Sanseau, Philippe, Chabot-Fletcher, Marie, Browne, Michael J.
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 01.04.2009
Elsevier
Subjects
Biological and medical sciences
Commerce - economics
Commerce - organization & administration
Drug Industry - economics
Drug Industry - organization & administration
Efficiency, Organizational - economics
General pharmacology
Genome, Human
Humans
Investments - economics
Investments - organization & administration
Medical sciences
Molecular Biology
Organizational Innovation - economics
Pharmaceutical technology. Pharmaceutical industry
Pharmacogenetics
Pharmacology. Drug treatments
Genetics
Pharmaceutical technology
Online AccessGet full text

Cover

More Information
Summary:The 1990s and early years of this century have seen a series of large-scale mergers and acquisitions in the Pharmaceutical and Biotech arena. These activities each required integration at multiple levels. One of the most important activities is the integration of the R&D pipelines of the participants. We outline the combined portfolio and bioinformatic strategy that was used, and detail the lessons learned for the longer term, from the GlaxoWellcome–SmithKline-Beecham merger in 2000. To date, this has been the largest merger of two equally sized Pharma R&D organisations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2008.12.001